Nuvation Bio Inc., a global commercial-stage oncology company, has outlined its ongoing initiatives and recent developments in its latest corporate presentation. The company has recently seen the approval of IBTROZITM (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1+ non-small cell lung cancer (NSCLC) in both the U.S. and China. Additionally, Nuvation Bio is advancing several other oncology programs, including safusidenib, a brain-penetrant mIDH1 inhibitor entering pivotal studies for diffuse IDH1-mutant glioma, and NUV-1511, a drug-drug conjugate currently in a Phase 1/2 study. Furthermore, NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company maintains a robust cash balance of $462 million, with potential access to up to $250 million in non-dilutive capital from Sagard Healthcare Partners to support its path to profitability. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。